Loading
Dr. Lal Path Labs Ltd. Stock: price and insider trades · India
No insider purchase over the last 90 days. The latest, by JAYESH HINGE, was filed 22 Aug 2024.
Insider Decl.
980
Thresholds
n/a
Buy Volume
€128,149
3 ops. · all time
Sell Volume
€90M
413 ops. · all time
Who traded when
BuySaleAmit Aggarwal12 sales
Om Prakash Manchanda11 sales
Rahul Sharma10 sales
Abhishek Aggarwal7 sales
Punit Sharma7 sales
Sanjay Kulshreshtha7 sales
+23 other insiders
Since the insiders bought
- -24.8%Entry ₹1,300.00 · Close at T+365 ₹977.25
- -43.8%Entry ₹2,104.30 · Close at T+365 ₹1,181.93
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Dr. Lal Path Labs Ltd. Buy (bullish), based on 26 analysts. Average price target: ₹2,018.08.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 8,724 of 26,280 companies
59.9
score / 100
Value32
Quality88
FCF yld1.5%
Earn yld1.6%
EV/EBITDA36.2x
ROE21%
Gross mgn81%
Net mgn18%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
₹1,847.60
Analyst consensus
26 analystsBuy
₹1,180.00Target ₹2,018.08(+9%)₹2,380.00
Income statement
Revenue₹27.6B
Gross profit₹22.3B81% margin
EBITDA₹8.5B31% margin
Net income₹5B18.7% margin
Valuation
PER (trailing)57.0x
PER (forward)42.1x
P/Book12.3x
Beta0.16
Balance sheet & cash
Market cap₹308.9B
Total debt₹2B
Free Cash Flow₹4.6B
Debt / Equity8%
Profitability & ownership
ROE21.5%
ROA13.3%
% insiders54.7%
% institutions32.7%
Last declaration on 30 September 2026
Declarations980 total
2,100 shares@ ₹965.000.0006% mcap9.1% of flowEquityESOPSEBI:5e863a6b51e3497e348846926f204989aeae9074
4,050 shares@ ₹965.400.0012% mcap1.0% of flowEquityESOPSEBI:383726478cdac50d9e5d4a1a37f0966769a349b8
750 shares@ ₹1,960.000.0005% mcap23.6% of flowEquityMarket SaleSEBI:d1112bab15e63f1bb6fc3057b55d334c96a1ea2c
750 shares@ ₹1,141.200.0003% mcap13.8% of flowEquityESOPSEBI:4c306949576c0c32985ed72386de94aa7f87d5a6
3,000 shares@ ₹1,215.800.9% of flowEquityESOPSEBI:aadcf11f93e52752298aa99134df9b6fe56cdd98
1,500 shares@ ₹1,980.000.0009% mcap11.2% of flowEquityMarket SaleSEBI:aeffedd9a37e1cbdbe917508621fc8293cec7988
2,000 shares@ ₹1,951.000.0012% mcap38.5% of flowEquityMarket SaleSEBI:4994b5f50b17ed68ff11db4e161610f15c6e3a25
2,000 shares@ ₹1,226.0024.2% of flowEquityESOPSEBI:2eda43bf952438112199abdcc90f358e9e4b77f7
1,000 shares@ ₹1,195.404.5% of flowEquityESOPSEBI:38fed8525b80155279a9393b101489df227d13e0
800 shares@ ₹965.0022.4% of flowEquityESOPSEBI:0959c8e314299131db02df31927528bd473b906e
1,000 shares@ ₹1,425.705.3% of flowEquityESOPSEBI:144d4aa641e169d5e2e688d18dbdb5efbfd178b4
4,500 shares@ ₹1,962.000.0027% mcap12.1% of flowEquityMarket SaleSEBI:0646122ecfe05e2072fc09774a36d2610277f674
800 shares@ ₹1,937.000.0005% mcap44.9% of flowEquityMarket SaleSEBI:47a63348a3717da39ecb37048476cb6f3be5480e
2,350 shares@ ₹1,084.600.6% of flowEquityESOPSEBI:32a113053e7d00c7efeaed27f2ce03b961de207a
400 shares@ ₹1,881.400.0002% mcap21.7% of flowEquityMarket SaleSEBI:8b8996cbda9f78abec95623db4fabb817639b7ae
400 shares@ ₹965.0011.1% of flowEquityESOPSEBI:40c8e6dffa5e9c01541aee67ada6c262e9d2bf90
2,000 shares@ ₹1,914.000.0012% mcap37.3% of flowEquityMarket SaleSEBI:1c680560914448cf2661d9399edd782fbd9b78ca
1,500 shares@ ₹1,926.700.0009% mcap10.7% of flowEquityMarket SaleSEBI:332acea0bec7c3502466a4991f5d74c02beb06f8
1,000 shares@ ₹1,960.000.0006% mcap2.7% of flowEquityMarket SaleSEBI:99664e6e435ea5009d666cfe2d3f1839ce02fe72
500 shares@ ₹1,934.500.0003% mcap7.0% of flowEquityMarket SaleSEBI:db275541a9cfb3a07c852201e1ae8b46b66d2267
3,000 shares@ ₹1,066.300.0010% mcap0.8% of flowEquityESOPSEBI:2cf700a58fcf4eee9041c4909b19c88cc7536e8e
500 shares@ ₹1,425.700.0002% mcap5.2% of flowEquityESOPSEBI:7eb75111d2a98d39da454e08bafd700e75726bd5
500 shares@ ₹965.000.0001% mcap12.1% of flowEquityESOPSEBI:f772d5223b541d17e2fc2f13079a9249405a01be
500 shares@ ₹1,886.000.0003% mcap23.7% of flowEquityMarket SaleSEBI:833c68627c5ee4396b5b1571123879b23367795d
2,050 shares@ ₹1,885.500.0012% mcap19.5% of flowEquityMarket SaleSEBI:4376e9523ad3d0f648588ab3af02364d5adac2d8
25 of 980 declarations
About Dr. Lal Path Labs Ltd.
Sales by the promoter (Hony) Brig. Dr. Arvind Lal dominate the Dr. Lal Path Labs Ltd. record: EUR 10,827,253 on September 4, 2025, EUR 7,337,400 on September 3, 2024, then EUR 5,543,777 on August 6, 2026 under the mention "Promoter and Director". In all, 413 sales represent EUR 89.7 million, with a median of EUR 23,609: many small trades. Purchases number only 3, worth EUR 128,149, including EUR 116,915 for Mridula Paliwal on March 24, 2022.
Most filings are of another kind: 561 are grants, and Dr. Lal PathLabs Employees Welfare Trust, an employee trust, filed 158, with no purchase or sale. Om Prakash Manchanda (92 filings, 68 sales), Bharath U (70) and Manoj Kumar Garg (44) follow, with Rahul Sharma (Director, 41).
Read moreShow less
The 980 filings published between May 20, 2021 and September 30, 2026 peak at 222 in 2024. They appear a median of 1 day after the trade, across 87 filers. This Indian healthcare company, listed on the Bombay Stock Exchange, is worth INR 308.9 billion; 54.7% of its capital is held by insiders. The last twelve months hold 134 filings, of which 53 sales and no purchase.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
